3,063 Shares in United Therapeutics Corporation $UTHR Bought by Quantitative Investment Management LLC

Key Points

• Quantitative Investment Management LLC has acquired a new investment in United Therapeutics Corporation, purchasing 3,063 shares valued at approximately $944,000.
• Numerous institutional investors, including Stifel Financial Corp and Price T. Rowe Associates Inc., have also increased their holdings in United Therapeutics, reflecting strong institutional support with 94.08% of the stock owned by such entities.
• United Therapeutics reported an EPS of $6.41 for its latest quarter, missing analysts' expectations, while the company had a revenue growth of 11.7% year-over-year.

Quantitative Investment Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,063 shares of the biotechnology company's stock, valued at approximately $944,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC boosted its holdings in United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after buying an additional 37 shares during the last quarter. Applied Finance Capital Management LLC boosted its holdings in United Therapeutics by 3.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after buying an additional 40 shares during the last quarter. Headlands Technologies LLC boosted its holdings in United Therapeutics by 1.5% in the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock worth $828,000 after buying an additional 40 shares during the last quarter. Cadence Bank boosted its holdings in United Therapeutics by 1.2% in the 1st quarter. Cadence Bank now owns 3,963 shares of the biotechnology company's stock worth $1,222,000 after buying an additional 47 shares during the last quarter. Finally, Dunhill Financial LLC boosted its holdings in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Finally, UBS Group raised their target price on shares of United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

United Therapeutics Trading Down 0.7%

United Therapeutics stock traded down $2.26 during trading on Friday, hitting $304.99. The company had a trading volume of 284,851 shares, compared to its average volume of 530,833. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The company's 50 day simple moving average is $298.38 and its 200-day simple moving average is $306.47. The stock has a market cap of $13.76 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 4.63 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the business posted $5.85 EPS. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock worth $24,537,839 over the last quarter. Company insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.